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Meningiomas are primary central nervous system (CNS) tumors that originate from the
arachnoid cells of the meninges. Recurrence occurs in higher grade meningiomas and
a small subset of Grade I meningiomas with benign histology. Currently, there are no
established circulating tumor markers which can be used for diagnostic and prognostic
purposes in a non-invasive way for meningiomas. Here, we aimed to identify potential
biomarkers of meningioma in patient sera. For this purpose, we collected preoperative
(n = 30) serum samples from the meningioma patients classified as Grade I (n =
23), Grade II (n = 4), or Grade III (n = 3). We used a high-throughput, multiplex
immunoassay cancer panel comprising of 92 cancer-related protein biomarkers to
explore the serum protein profiles of meningioma patients. We detected 14 differentially
expressed proteins in the sera of the Grade I meningioma patients in comparison to
the age- and gender-matched control subjects (n = 12). Compared to the control
group, Grade I meningioma patients showed increased serum levels of amphiregulin
(AREG), CCL24, CD69, prolactin, EGF, HB-EGF, caspase-3, and decreased levels of
VEGFD, TGF-α, E-Selectin, BAFF, IL-12, CCL9, and GH. For validation studies, we
utilized an independent set of meningioma tumor tissue samples (Grade I, n = 20;
Grade II, n = 10; Grade III, n = 6), and found that the expressions of amphiregulin
and Caspase3 are significantly increased in all grades of meningiomas either at the
transcriptional or protein level, respectively. In contrast, the gene expression of VEGF-D
was significantly lower in Grade I meningioma tissue samples. Taken together, our study
identifies a meningioma-specific protein signature in blood circulation of meningioma
patients and highlights the importance of equilibrium between tumor-promoting factors
and anti-tumor immunity.
Keywords: meningioma, proximity extension assay, biomarker, serum biomarker, CNS tumors, high-throughput
immunoassay cancer panel
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INTRODUCTION
Meningiomas account for 53.1% of all non-malignant brain
and other CNS tumors (1). The majority of meningiomas with
documented WHO grade is Grade I (80.6%) (1). These benign
tumors can remain dormant without causing any symptoms
for a long time, which arguably represents the major challenge
in early detection of meningiomas (2). Intriguingly, recurrence
frequently occurs in tumors with benign histology, and recent
studies revealed that coexistence of del(1p36) and monosomy
14 is associated with early recurrence of meningiomas (3).
Mutations or deletions on the NF2 gene, which is located on
22q12.2 locus and encodesMerlin, have been originally described
in meningiomas as an oncogenic driver gene (4). However,
recent studies showed that other genetic alterations in TRAF7,
PIK3CA, KLF4, POLR2A AKT1, SMO, SUFU, and SMARCB1
genes are involved in meningioma pathogenesis (5–8). Grade
II and III meningiomas are also associated with few specific
recurrent somatic mutations, such as SMARCE1 mutations
in clear cell meningioma and BAP1 mutation in a subset of
rhabdoid meningiomas (9). Treatment protocol for meningomas
is closely associated with tumor location, grade and includes
surgery followed by fractionated external beam radiation therapy
(EBRT) (10).
To date, no consensus has been established on specific
biomarkers toward early diagnosis or prognosis for
meningiomas. Most CNS tumors are currently diagnosed
primarily radiology-based modalities like CT or MRI scans
followed by validation with genetic or IHC-based diagnostic
markers. The major challenge in the radiology-based technology
is that the tumors can be detected only when they reach to a
certain size, which creates worse prognostic risk as tumor is
transformed from benign to malignant forms.
While CT and MRI are usually sufficient for diagnosis of
meningiomas, other tumors and diseases may radiologically
mimic meningioma and complicates the diagnosis (11). In
addition, imaging modalities are only able to detect tumors
when they reach a certain size. Given the slow growth rate
of meningiomas, these tumors may remain undiagnosed for
extended periods of time. Grade I meningiomas have a mean
tumor age of >20 years, highlighting requirement of longer
time periods to diagnose tumor. Furthermore, the average time
between initial cell transformation and detection of tumor mass
has been reported as 26.3 years in fibrous meningiomas, and
17.8 years in meningothelial meningiomas (12). Slow growth
rate of meningiomas also complicates early prediction of the
meningioma progression, and recurrence that occurs in ∼30%
of Grade I meningiomas, 50% of Grade II and 80% of Grade III
meningiomas (13, 14).
Currently, there is no serum-based diagnostic and/or
prognostic marker available to monitor transition stages
of meningiomas from benign state to malignant form.
Identification of such markers would not only improve
early detection of meningioma, but also improve survival rate of
meningioma patients.
Proteomics analysis has been used to investigate disease
pathophysiology and identify potential surrogate disease markers
for brain tumors (15–18). However, only a small number of
reports focused on protein profiling of meningioma tumor
specimens (19, 20) and serum samples (21). The majority of
proteomics studies employed meningioma tumor tissues (22–
25), while others used biological fluids, such as cerebrospinal fluid
and serum (21).
In this study, for the search of potential biomarkers
for meningiomas, we used a high-throughput, multiplex
immunoassay cancer panel based on the proximity extension
assay (PEA) to screen a set of 92 cancer-related protein markers.
The serum protein expression profiles of Grade I (benign,
n = 23), Grade II (atypical, n = 4), and Grade III (anaplastic,
n = 3) meningioma patients were analyzed in relation to the
healthy control subjects (n = 12). Furthermore, our validation
studies using an independent set of meningioma tumor tissues
(Grade I, n= 20; Grade II, n= 10; and Grade III, n= 6) identifies
a protein biomarker signature in meningioma patient sera.
MATERIALS AND METHODS
Study Population
The screening cohort consisted of Grade I (n= 23), Grade II (n=
4), and Grade III (n= 3) meningioma patients. The independent
validation cohort consisted of Grade I (n = 20), Grade II (n =
10), Grade III (n = 6) meningioma patient tissue samples that
were collected after the surgery and stored at −80◦C. Patients
were operated at the Vienna General Hospital (Vienna, Austria).
This study was carried out in accordance with the Good Scientific
Practice recommendations of the ethics committee of Medical
University of Vienna. All subjects gave written informed consent
in accordance with the Declaration of Helsinki. The protocol was
approved by the local ethics committee of the Medical University
of Vienna.
Serum Collection
Preoperative blood samples were collected before any therapeutic
intervention (surgery, chemotherapy, radiotherapy). Blood
samples were let to stand at 4◦C for 60min, and then centrifuged
at 1,100× g for 10min. Serum samples were aliquoted and stored
at−80◦C.
Protein Detection With Proximity Extension
Assay (PEA)
Serum samples from Grade I (n = 23), Grade II (n = 4), and
Grade III (n = 3) meningioma patients were delivered to AIT
Molecular Diagnostics. Age- and gender-matched control serum
samples (n = 12) were provided by AIT Molecular Diagnostics.
OLINK ProSeek Oncology-I Panel was used to detect expression
of 92 cancer-related proteins (https://www.olink.com/products/
oncology) (Supplementary Table 1). Briefly, 1µL serum samples
were incubated with 92 antibody pairs of oligonucleotide-
labeled antibodies. Binding of the antibody pair to the
antigen brings the oligonucleotides to close proximity, and
a new PCR target sequence is formed by a proximity-
dependent DNA polymerization event. The resulting sequence is
subsequently detected and quantified by high-throughput real-
time PCR (BioMarkTMHD System, Fluidigm Corporation). The
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fluorescent signals generated in real-time PCR directly correlates
with protein abundance. Raw Cq values were normalized by
subtracting the Cq values for the extension control and compared
to that of the corresponding background reaction. The resulting
ddCq values were used for further analysis and represented as
Normalized Protein Expression (NPE) in Log2 scale.
Functional Analysis
Differentially expressed proteins (FDR = 0.01) identified in
Reproducibility-optimized test statistic (ROTS) were analyzed
with the PANTHER database version 14.0 (http://www.
pantherdb.org/) (26). The list of proteins was uploaded and
mapped against the reference dataset (Homo sapiens).
Real Time-qPCR
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems) was used to reverse transcribe 1,000 ng of total
RNA. Quantitative real-time PCR reactions were performed
using the Universal PCR Master Mix (Thermo Scientific) on a
7300 Real-Time PCR system (Applied Biosystems). 1Ct values
were calculated according to the following formula (27): 1Ct
= CtTarget – CTReference. This equation considers Ct values to be
proportional to the negative logarithm of gene expression. Thus,
1Ct values are positively related to the expression of gene of
interest. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was used as a reference gene to normalize gene expression.
Primer sequences are shown in Supplementary Table 3.
Western Blotting
Western blotting was performed as previously described
(28). The following primary antibodies were used: Caspase-
3 (1:2,000, BD Biosciences) and beta-actin (1:5,000, Sigma-
Aldrich). Densitometric analysis was performed on scanned
blot images. Images were transformed to gray-scale on ImageJ
software (v.1.50i, National Institutes of Health, USA). For each
blot, a lane normalization factor was calculated by dividing the
signal of each loading control band with that of the highest signal
of loading control on the blot. The calculated lane normalization
factor was then used to normalize caspase 3 band signals.
Statistical Analysis
Reproducibility-optimized test statistic (ROTS) algorithm
(26) was used to identify differentially expressed proteins.
Comparisons were done between Grade I preoperative samples
and control samples. The default parameters (B= 1,000, K = 19)
were used for all comparisons. Proteins with a false discovery
rate (FDR) below 0.01 were considered as significant.
RStudio version 1.1.414 and Prism version 8.0.1 (GraphPad
Inc.) were used for statistical analysis. Multiple tests (Anderson-
Darling, D’Agostino and Pearson, Shapiro-Wilk, and
Kolmogorov-Smirnov tests) were used to test for log-normal
distribution. For proteins that followed normal distribution,
paired t-test was used to compare protein expression between the
samples. For proteins that did not follow normal distribution,
Wilcoxon matched-pairs signed rank test was used. Brown-
Forsythe ANOVA test with Dunnett’s multiple comparison was
used to compare mRNA expression levels among meningioma
grades. P < 0.05 were considered statistically significant.
RESULTS
Serum Protein Profiling With a
High-Throughput, Multiplex Immunoassay
Cancer Panel Using the Proximity
Extension Assay
To identify protein biomarkers associated with meningioma,
we used a high-throughput, multiplex immunoassay cancer
panel consisting of 92 putative cancer-related human
proteins that are involved in key biological processes, such
as angiogenesis, cell-to-cell signaling, cell-cycle control, and
inflammation which play central roles in cancer metabolism.
The putative protein biomarkers that are selected based on
the analyses of commonly used bioinformatic databases [e.g.,
Uniprot, Human Protein Atlas, Gene Ontology (GO), and
DisGeNET] are then classified according to their functional
protein groups, roles in biological processes, associations
with diseases, and expression patterns in tissues (Olink
Proteomics) (Supplementary Table 1). The multiplex nature
of this immunoassay-based cancer panel enables simultaneous
analysis of large sample numbers, and its coupling with the PEA
technology provides uncompromised data quality. Thus, taking
advantage of this technology, we analyzed 30 serum samples
obtained from meningioma patients prior to the surgery, and
12 control serum samples from the age- and gender-matched
healthy subjects.
Our results showed that 14 proteins were differentially
expressed in the Grade I meningioma patients compared to
healthy control subjects (Figure 1). Of those, seven proteins,
caspase-3, CD69, prolactin, epidermal growth factor (EGF),
chemokine (C-C) ligand 24 (CCL24), amphiregulin (AREG),
and heparin-binding EGF (HB-EGF) were highly expressed in
the Grade I meningioma samples (Figure 1B), while, the other
seven proteins, vascular endothelial growth factor D (VEGF-
D), transforming growth factor alpha (TGF-α), E-selectin, B-
cell activating factor (BAFF), interleukin-12 (IL-12), chemokine
(C-C motif) ligand 9 (CCL9), and Growth Hormone were
reduced in the meningioma serum samples, compared to
healthy control subjects (Figure 1C andTable 1). The PANTHER
pathway analyses revealed that differentially expressed proteins
are linked to the EGF receptor signaling (EGF, amphiregulin,
HB-EGF, TGF-α), apoptosis (caspase-3), immunomodulation
(prolactin, CD69, CCL24, IL-12, CCL9, BAFF), and angiogenesis
(VEGF-D). Of note, the expression levels of 16 analytes were
below the limit of detection in more than 20% of all samples.
These markers were excluded from the downstream analyses
(Supplementary Table 2).
We further questioned whether the differentially
expressed proteins detected in the blood circulation of
the meningioma patients were correlated with the tumor
grade. Although the patterns of the protein profiles of the
Grade II and Grade III patients were comparable to that
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FIGURE 1 | Differentially expressed proteins between meningioma patients and control subjects. ROTS algorithm was used to identify differentially expressed proteins
between Grade I meningioma patients and healthy control subjects (A). Heatmap visualization of differentially expressed proteins (B,C). Comparison of protein levels
across tumor grades (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
of the Grade I patients, we were unable to statistically
analyze the differences between these groups due to the
small sample sizes of Grade II (n = 4) and Grade III
(n= 3) patients.
Validation Cohort Using an Independent
Set of Meningioma Tumor Tissues
For validation studies, we enrolled an independent set of 49
meningioma tissue samples including Grade I, n = 20; Grade II,
n= 10; grade III, n= 6, as well as NormalWhite Matter (NWM),
n = 13 as control tissue samples. As shown in Figure 2A, we
found a significant increase in the gene expression levels of
amphiregulin in the Grade I meningiomas, while the VEGF-
D mRNA levels were relatively decreased, compared to the
control NWM tissue samples. In addition, we analyzed the
protein expression levels of Caspase 3 enzyme in the tissue
samples, and found that the protein levels of Caspase 3 are
significantly higher in all grades of meningioma tissue samples
compared to the control group (Figures 2B,C). We did not
observe significant difference in the gene expression profiles
of CD69, BAFF, HB-EGF, E-Selectin (Supplementary Figure 1)
suggesting that these proteins may not exclusively originate
from meningioma tumor cells, but rather may be secreted from
other cell types, such as immune system cells that circulate in
the bloodstream.
DISCUSSION
Identification of non-invasive protein biomarkers has been a
great interest for cancer diagnosis. In this study, we searched for
putative cancer biomarkers that can be used for diagnostic and
prognostic purposes in meningioma patients. For this discovery
study, we employed a commercial cancer panel based on a high-
throughput, multiplex immunoassay that is equipped with the
PEA technology, and detected serum protein profiles of the
meningioma patients (n = 30) in comparison to the control
subjects (n = 12). By taking advantage of the technology of
PEA that requires low sample input to carry out multiplexed
assays with good sensitivity and specificity (29, 30), we identified
14 differentially expressed proteins in the sera of the Grade
I meningioma patients relative to the healthy control subjects
(Figures 1A–C). In addition, the proteins differentially expressed
in the Grade I meningioma patient sera were also detected in
a small set of Grade II (n = 4) and Grade III (n = 3) patient
sera (Figures 1A,B). However, due to the small sample size
of higher grade meningioma patient samples, we were unable
to determine how significantly protein expressions differed
between the tumor grades. In order to validate our potential
biomarkers, we utilized an independent cohort containing 36
meningioma tumor samples, and found that amphiregulin and
Caspase 3 are significantly increased in meningioma tumor
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TABLE 1 | Differentially expressed proteins between Grade I meningioma patients
and control subjects.
Protein log2FC
(Meningioma/
Control)
Linear FC
(Meningioma/
Control)
P-value FDR
Caspase-3 2.13 4.38 0 0.00
CD69 2.09 4.27 3.29E-05 0.00
Prolactin 1.37 2.58 4.47E-04 0.00
EGF 1.18 2.26 2.89E-03 0.00
CCL24 0.79 1.72 8.68E-03 0.00
Amphiregulin 0.78 1.72 5.66E-03 0.00
HB-EGF 0.76 1.69 2.16E-03 0.00
VEGFD −0.61 0.66 8.64E-03 0.00
TGF-α −0.67 0.63 9.88E-03 0.00
E-selectin −0.69 0.62 9.55E-03 0.00
BAFF −0.93 0.53 4.54E-04 0.00
IL-12 −1.00 0.50 8.41E-03 0.00
CCL9 −1.33 0.40 2.89E-04 0.00
Growth
Hormone
−1.66 0.32 1.82E-03 0.00
FC, fold change; FDR, false discovery rate.
tissues, while VEGF-D is relatively lower in comparison to the
control NWM tissue samples (Figure 2). The other candidate
proteins, Prolactin, HB-EGF, E-Selectin, CD69, and BAFF that
were emerged from the cancer-panel protein screening were not
detected in our independent set of meningioma tissue specimens
(Supplementary Figure 1).
In our study, caspase-3 emerged as the top differentially
expressed protein showing increased expression levels in our
dataset of the meningioma patient sera (n = 30). Caspase-
3 is a central effector of apoptosis (31). However, sublethal
activation of caspase-3 has been shown to promote genetic
instability and carcinogenesis (32). In addition, caspase-3 was
proposed to play a key role in the repopulation of tumors
in response to radiotherapy, and its activity is correlated with
increased rate of recurrence and death in cancer patients (33).
Our findings showing increased serum levels of caspase-3 are
supported by an earlier study reporting an increased caspase-
3 immunoreactivity in meningioma tissues, in which Grade II
and Grade III meningioma tissues exhibited higher scores of
immunopositivity relative to the benign Grade I meningioma
tissues (34). In addition, the same study identified caspase-3 as an
independent predictor of early recurrence (34). Elevated serum
caspase-3 levels in meningioma patients, along with its reported
increased tissue levels, may indicate a clinical value for caspase-
3 in meningioma as a predictive marker of benign-to-malignant
transformation. In line with our study, a recent study has also
shown that increased caspase-3 expression in primary atypical
and malignant meningiomas is correlated with the higher grade
of meningioma (35).
CD69, an early activation marker of lymphocytes and natural
killer cells (36) is another hit detected in our screening
study. CD69 is an important regulator of immune responses
that take part in cytokine release, homing and migration of
lymphocytes (37, 38). However, the state of tissue environment
and cytokine spectrum could differentially regulate its role in
immune responses (39). In murine models, CD69 deficiency
is associated with enhanced anti-tumor immunity and longer
survival (40). Recently, CD69 has been indicated in the induction
of T cell exhaustion in a breast cancer tumor model in mice,
where anti-CD69 antibody treatment was proven to enhance
anti-tumor activity, pointing CD69 as a novel target for cancer
immunotherapy (41). On the contrary, high levels of tumor-
infiltrating CD4+CD69+ T cells are associated with good
prognosis in head and neck squamous cell carcinoma (42). In
meningioma, an increased infiltration of CD69+ lymphocytes,
along with tissue macrophages and natural killer cells has been
reported, which is specifically associated with the cases carrying
a distinct cytogenetic profile of isolated monosomy 22/del(22q)
that shows a better prognosis (43). Thus, increased infiltration of
meningiomas by activated lymphocytes including CD69+ subsets
may be associated with immune surveillance, and elimination
of tumor cells that restricts the tumor growth (43). Given that
our study identified CD69 as a putative serum biomarker in
meningiomas, it is plausible to think that this may be caused
by the increased presence of tumor growth-limiting CD69+
lymphocytes in the circulation of Grade I meningioma patients.
However, further studies are required to investigate the presence
of CD69+ lymphocytes in the blood stream of the meningioma
patients and its correlation with serum CD69 protein for possible
clinical applications.
Our study identified two different ligands of EGFR,
amphiregulin (AREG) and heparin-binding EGF (HB-EGF)
that are elevated in the sera of Grade I meningioma patients.
Among those, our validation studies showed that the expression
of amphiregulin is significantly upregulated in the meningioma
tumor tissues, compared to the control NWM specimens.
Amphiregulin is a secreted EGFR ligand that regulates cellular
growth and differentiation, immunity, inflammation, and tissue
repair (44, 45), and it is overexpressed in a variety of cancers
(44, 46, 47). Amphiregulin is originally described as an epithelial-
and mesenchymal cell-derived factor, however, recent studies
show that it is expressed by multiple populations of activated
immune cells including dendritic cells and CD4+ T cells (45).
It is likely that elevated levels of amphiregulin in meningioma
patient sera may reflect the response of immune system and/or
the ongoing tissue repair owing to the tumor mass. Alternatively,
amphiregulin and HB-EGF may act as activators of EGFR that
is overexpressed in meningiomas, supporting tumor growth and
malignancy (48).
Prolactin was found in elevated levels in the sera of our
Grade I meningioma patient group in our study. However, we
did not detect an increase in prolactin levels in meningioma
tissues. Interestingly, some increase in prolactin receptor levels in
meningiomas has been also reported earlier (49, 50). Considering
that prolactin stimulates growth of primary meningioma cells
in vitro (51), further studies are necessary to reveal the clinical
importance of serum prolactin levels in meningioma patients.
CCL24 is a chemokine with well-studied roles in allergies
(52). In the context of cancer, CCL24 expression has been shown
to associate with poor prognosis in colorectal cancer and also
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FIGURE 2 | Validation studies of cancer-panel protein screening candidates. For validation studies, by using an independent meningioma tissue specimen set, n = 36
[Grade I (n = 20), Grade II (n = 10), and Grade III (n = 6)], the expressions of the indicated genes were analyzed by RT-qPCR, Normal white matter (NWM) tissue
samples were used as control (AREG, NWM vs. Grade I, ****p < 0.0001, Brown-Forsythe ANOVA test with Dunnett’s multiple comparison; VEGF-D, NWM vs. Grade I,
**p < 0.01, Brown-Forsythe ANOVA test with Dunnett’s multiple comparison) (A). Western blot images showing caspase-3 protein expression in tumor lysates
obtained from Grade I (n = 18), Grade II (n = 10), and Grade III (n = 7) meningiomas (B). Densitometric analysis of Western blot bands (NWM vs. Grade I, ***p <
0.001, Brown-Forsythe ANOVA test with Dunnett’s multiple comparison; NWM vs. Grade II, and NWM vs. Grade III, *p < 0.05, Brown-Forsythe ANOVA test with
Dunnett’s multiple comparison) (C).
contribute to hepatocellular carcinomamalignancy via the RhoB-
VEGFA-VEGFR2 angiogenesis pathway (53, 54). In our study,
we detected slightly higher serum levels of CCL24 in Grade
I meningioma patients in comparison to the control subjects.
However, clinical value of this finding is yet to be understood
in meningiomas.
IL-12 is a cytokine that is mainly produced by antigen-
presenting cells, and it has well-established anti-tumor activity
(55, 56). IL-12 serum levels were found relatively reduced in
meningioma and glioblastoma patients (57). Consistently, our
study revealed that Grade I meningioma patients have reduced
serum IL-12 levels compared to the control subjects.
VEGF plays a pivotal role in angiogenesis, and its expression
in meningiomas was reported to associate with unfavorable
prognosis and recurrence (58–60). Intriguingly, several studies
addressing serum VEGF levels in meningioma depicted some
contradictory results. Stockhammer et al. reported that serum
VEGF-A concentration is higher in patients with central nervous
system tumors, including meningioma, than in patients with
no tumor diagnosis (61). Nowacka et al. reported higher serum
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VEGF-A levels in meningioma patients (62). In our study, we
detected that the serum levels of VEGF-D, a member of the
VEGF family that plays a role in glioblastoma angiogenesis (63),
is relatively lower in the Grade I meningioma patients compared
to the control subjects. Furthermore, we showed that the gene
expression of VEGF-D is significantly lower in meningioma
tumor tissues relative to the control NWM tissues. In line with
our findings, another group reported lower serum levels of VEGF
in meningioma patients where control subjects had higher levels
of serum VEGF (64). Although the exact mechanism of lower
serum and tissue levels of VEGF in meningioma is unknown,
further research is required if VEGF levels could have some
prognostic value in following up tumor recurrence.
B-cell activating factor (BAFF), a member of the TNF
superfamily is one of the critical factors controlling B-cell
homeostasis, and its interaction with its ligand/receptor regulates
the survival and proliferation of malignant cells (65, 66).
High BAFF serum levels have been detected in autoimmune
disorders, including rheumatoid arthritis and systemic lupus
erythematosus, as well as in the malignancies, such as non-
Hodgkin’s lymphoma, B-CLL, and multiple myeloma (65).
Interestingly, BAFF is expressed in astrocytes and astrocyte-
derived BAFF promotes B-cell survival in multiple sclerosis and
primary CNS lymphoma (67). Our findings revealing low levels
of circulating BAFF in Grade I meningioma might indicate an
autocrine control of the BAFF system that can counteract the
malignant progression of meningiomas.
Similarly, we observed that the patients with Grade I
meningioma had lower levels of serum E-selectin, compared to
the healthy control subjects. Given the roles of selectins in cancer
progression and metastasis (68), low levels of E-selectin might
reflect the benign state of meningiomas.
Chemokines and their receptors play important roles
in determining the metastatic destination of cancers (69).
Chemokine CCL9 (MIP-1γ) is a ligand for the CCR1/CD191
receptor present on T cells, monocytes, macrophages, some
myeloid-derived suppressor cells, and osteoclasts (70), and it
is a potent chemo-attractant for immune cells (71). Moreover,
CCL9/CCR1 signaling has been shown to recruit myeloid
progenitors to tumor area, leading to progression of adenomas
to carcinomas and also enhancing tumor invasion (70, 72–74).
CCL9 has also been suggested as a fair candidate for anti-
metastasis treatment of cancer (75). In our study, circulating
CCL9 appeared to be lower in Grade I meningioma relative to the
control group, in a similar way to the serum levels of VEGF, BAFF,
E-selectin, and IL-12. It is conceivable to postulate that low serum
levels of CCL9, VEGF, BAFF, E-selectin, and IL-12 might reflect
the benign state of the disease that may be used for monitoring
the tumor progression from benign to malignant form.
In sum, this study provides a list of candidate proteins that
could potentially be utilized as diagnostic/prognostic circulating
biomarkers of meningioma. Our validation studies in an
independent set of meningioma tissue specimens provide further
evidence that caspase-3, amphiregulin and VEFG-D might
be promising markers to monitor the status of meningiomas
through a non-invasive manner by using patient blood.
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